Rabbit Recombinant Monoclonal NAGLU/NAG antibody - conjugated to Alexa Fluor® 750.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
UFHSD1, NAGLU, Alpha-N-acetylglucosaminidase, N-acetyl-alpha-glucosaminidase, NAG
Rabbit Recombinant Monoclonal NAGLU/NAG antibody - conjugated to Alexa Fluor® 750.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
NAGLU/NAG also known as alpha-N-acetylglucosaminidase is an enzyme with a molecular weight of approximately 83 kDa. This enzyme localizes in the lysosome where cells express it across various tissues. NAGLU plays a significant role in the breakdown of heparan sulfate which is a glycosaminoglycan found on cell surfaces and in the extracellular matrix. Its enzymatic action involves the cleavage of terminal alpha-N-acetylglucosamine residues during lysosomal degradation.
NAGLU facilitates the degradation of heparan sulfate in conjunction with other enzymes as part of a degradation complex within the lysosome. NAGLU's action is essential for maintaining the balance of heparan sulfate levels inside cells which is important for cellular health and function. Without the proper function of this enzyme heparan sulfate accumulates within lysosomes due to incomplete catabolism leading to cellular dysfunction and related pathologies.
NAGLU functions critically in the glycosaminoglycan degradation pathway. This pathway involves several enzymes including iduronate-2-sulfatase which acts upstream of NAGLU. Together they ensure the breakdown of complex sugars such as heparan sulfate. NAGLU also participates in the larger lysosomal degradation pathway collaborating with other lysosomal enzymes to ensure proper breakdown and recycling of cellular materials.
Disruptions in NAGLU function are directly linked to mucopolysaccharidosis type IIIB (MPS IIIB) also known as Sanfilippo syndrome type B. This disorder results from mutations that impair NAGLU activity causing heparan sulfate accumulation and neurodegeneration. Additionally deficient NAGLU activity may intersect with pathologies involving heparan sulfate binding proteins impacting cellular signaling and contributing to disease progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com